|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Pneumococcal vaccination: current and future issues
Karolinska Institutet and Dept of Infectious Diseases, Karolinska Hospital, Stockholm, Sweden
CORRESPONDENCE: Å. Örtqvist, Dept of Infectious Diseases, Karolinska Institutet, Karolinska Hospital, SE-17176, Stockholm, Sweden. Fax: 46 851771804
Keywords: conjugate vaccines, polysaccharide, revaccination, Streptococcus pneumoniae, vaccination
Received: August 9, 2000
Accepted October 3, 2000
Abstract
Infection with Streptococcus pneumoniae remains a major global health burden meaning the development of effective vaccines is urgently needed. The current 23-valent polysaccharide vaccine has been shown to prevent pneumococcal pneumonia in immunocompetent young adults, but not in elderly persons.
However, in prevention of invasive pneumococcal disease, the vaccine is efficacious in the elderly and may also be effective in some groups of immunocompromised patients. The polysaccharide vaccine is, therefore, recommended in all older (
In children <2 yrs of age, the new polysaccharide-protein conjugate vaccines, including 7–11 serotypes, seem to be effective in the prevention of invasive disease, severe pneumonia and serotype-specific (and vaccine-related types) otitis media. The low serotype coverage, need for repeated doses, and high price, may decrease the usefulness of the new conjugates. However, the included serotypes correspond to those most often associated with penicillin resistance and vaccination is, therefore, a possible tool in limiting the spread of antibiotic-resistant pneumococci.
55–65 yrs of age) adults and in young children (>2 yrs of age) who have a high risk for pneumococcal disease. Revaccination can be safely performed and is recommended 5 yrs after the first dose.
This article has been cited by other articles:
|
|
 |
|
  G. Rajam, G. M. Carlone, and S. Romero-Steiner Functional Antibodies to the O-Acetylated Pneumococcal Serotype 15B Capsular Polysaccharide Have Low Cross-Reactivities with Serotype 15C Clin. Vaccine Immunol., September 1, 2007; 14(9): 1223 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Alfageme, R Vazquez, N Reyes, J Munoz, A Fernandez, M Hernandez, M Merino, J Perez, and J Lima Clinical efficacy of anti-pneumococcal vaccination in patients with COPD Thorax, March 1, 2006; 61(3): 189 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Meyer Aging Proceedings of the ATS, December 1, 2005; 2(5): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Wasfy, G. Pimentel, M. Abdel-Maksoud, K. L. Russell, C. P. Barrozo, J. D. Klena, K. Earhart, and R. Hajjeh Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003 J. Antimicrob. Chemother., June 1, 2005; 55(6): 958 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kong and G. L. Gilbert Using cpsA-cpsB sequence polymorphisms and serotype-/group-specific PCR to predict 51 Streptococcus pneumoniae capsular serotypes J. Med. Microbiol., December 1, 2003; 52(12): 1047 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Lowy and I. H. Frazer Chapter 16: Prophylactic Human Papillomavirus Vaccines J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 111 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schwaiger, A. M. Wolf, P. Robatscher, B. Jenewein, and B. Grubeck-Loebenstein IL-4-Producing CD8+ T Cells with a CD62L++(bright) Phenotype Accumulate in a Subgroup of Older Adults and Are Associated with the Maintenance of Intact Humoral Immunity in Old Age J. Immunol., January 1, 2003; 170(1): 613 - 619. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |